Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide versus insulin glargine study in type 2 diabetes
NL-OMON26218Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2004
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Exenatide with Insulin glargine (2 arms). Primary endpoint: Glycemic control and beta-cell function. Started Oct 2004; status: active, not recruiting.
02
Drugs
exenatideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON26218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26218.